Author: Han, Ximeng ; Alsayer, Mohammed ; Alaidarous, Sondus ; Sun, Yani ; Ren, Xiaolei ; Robinson, Amy ; Clark, Jordan J ; Zhou, En-Min ; Hiscox, Julian A ; Sharma, Parul ; Kipar, Anja ; Bentley, Eleanor G ; Mu, Yang ; Zhao, Qin ; Stewart, James P

Myosin heavy chain 9 (MYH9) has been identified as a crucial factor in gammaherpesvirus infection. Murine gammaherpesvirus 68 (MHV-68) was used as an appropriate viral model for investigating gammaherpesviruses in vivo and developing antiviral treatments. However, the roles of MYH9 in MHV-68 infection have not been documented. In the study, the relationship between the expression of MYH9 and MHV-68 infection and MYH9 as the antiviral target were analyzed. The results revealed that MYH9 was enriched on the cell surface and co-localized with MHV-68 upon viral infection. Knocking down MYH9 with siRNA or using the specific inhibitor of MYH9 activity, Blebbistatin, resulted in the decreasing of MHV-68 infection. Furthermore, polyclonal antibodies against MYH9 reduced infection by approximately 74% at a dose of 100 μg/ml. The study determined that MYH9 contributes to MHV-68 infection by interacting with viral glycoprotein 150 (gp150) in the BHK-21 cell membrane. The specific region of MYH9, amino acids 1811-1960 (C-150), was identified as the key domain involved in the interaction with MHV-68 gp150 and was found to inhibit MHV-68 infection. Moreover, C-150 was also shown to decrease HSV-1 infection in Vero cells by approximately 73%. Both C-150 and Blebbistatin were found to inhibit MHV-68 replication and reduce histopathological lesions in vivo in C57BL/6J mice. Taken together, these findings suggested that MYH9 is crucial for MHV-68 infection through its interaction with viral gp150 and that C-150 may be a promising antiviral target for inhibiting MHV-68 infection in vitro and in vivo.

01 Nov 2017·Journal of Dairy ScienceQ1 · AGRICULTURAL & FORESTRY SCIENCE

Effects of amount of colostrum replacer, amount of milk replacer, and housing cleanliness on health, growth, and intake of Holstein calves to 8 weeks of age

Q1 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Deikun, L L ; Hill, T M ; Schlotterbeck, R L ; Quigley, J D

Newborn Holstein bull calves (n = 96) were assigned randomly at birth to receive 150 g (C150) or 450 g (C450) of IgG in the first 24 h of life from a lacteal-based colostrum replacer in 2 trials. Mass of product fed was 500 and 1,500 g, respectively. Replacer was reconstituted with warm water and administered by esophageal feeder at approximately 1, 6, and 12 h of age. Thereafter, calves were fed 2 L of whole milk twice daily at approximately 0700 and 1700 h until transported to the experimental facility at 2 to 3 d of age. Calves fed C450 had greater serum total protein and IgG concentrations at 2 to 3 d of age. Failure of passive transfer of immunity (serum IgG <10 g/L) was detected in 100 and 11% of calves fed C150 and C450, respectively. Calves (n = 48) in trial 1 were assigned randomly within colostrum group to receive 0.68 kg/d of milk replacer (MR) for 42 d, and then 0.34 kg/d for 7 d (moderate MR, MMR) or 1 kg/d of MR for 5 d, 1.36 kg/d for 37 d, and 0.68 kg/d for 7 d (high MR, HMR). Starter and water were available for ad libitum consumption. Calves fed HMR had greater average daily gain, higher average fecal scores, more days with abnormal fecal scores, and more medical days than calves fed MMR. Calves fed HMR also had lower starter intake and tended to have lower gain-to-feed ratio than calves fed MMR. Calves fed C450 and MMR began eating calf starter earlier and ate more starter than other groups from 3 wk. In trial 2, calves (n = 48) were assigned randomly within colostrum group to housing in nursery pens bedded with clean, dry straw (clean bedding) or soiled straw used in previous studies (dirty bedding). Milk replacer was fed at 0.68 kg/d for 39 d, and then 0.34 kg/d for 3 d along with free-choice texturized starter and water. Calves fed C450 had fewer days with abnormal fecal scores and days with medical treatments compared with calves fed C150. Calves housed in dirty bedding tended to grow more slowly and have lower gain-to-feed ratio than calves housed with clean bedding. Temporal changes in serum IgG and total protein varied by treatment. Serum IgG in calves fed C150 varied little from 0 to 4 wk and increased thereafter, whereas IgG in calves fed C450 declined to 4 wk (estimated half-life = 23.9 d) and increased thereafter. Differences in serum IgG concentrations caused by feeding different amounts of colostrum replacer did not markedly affect growth or intake when calves were fed different amounts of milk replacer or when they were housed with clean or dirty bedding.

01 Sep 2017·International Journal for Vitamin and Nutrition ResearchQ4 · MEDICINE

Effects of Curcumin on Alveolar Bone Loss in Experimental Periodontitis in Rats: A Morphometric and Histopathologic Study

Q4 · MEDICINE

Article

Author: Cansın Karakan, Nebi ; Lektemur Alpan, Aysan ; Goze, Fahrettin ; Akpinar, Aysun ; Calisir, Metin ; Poyraz, Omer

Abstract. Background: Curcumin is found in the rhizomes of the turmeric plant that has been showed antioxidant and anti-inflammatory effect. The aim of this study was to evaluate the effects of systemic curcumin therapy on alveolar bone loss in an experimental periodontitis model in rats. Material and Methods: Thirty-two male Wistar rats were randomly divided to 4 groups: 75 mg/kg/daily curcumin (C75; n =8), 150 mg/kg/daily curcumin (C150; n =8), Control (n =8), and Ligated (n =8). Curcumin was administrated using gastric gavage. After 12 days, the rats were sacrificed. Right mandibles samples were histopathologically examined. Alveolar bone loss was measured. Interleukin 1β (IL-1β) and interleukin 10 (IL-10) were evaluated in the serum samples and gingival homogenates. Results: The measurements of alveolar bone loss in the mandibular molars revealed significantly higher bone-loss values in the Ligated group than the Control, C75 and C150 groups. The IL-1β levels in the gingival homogenates were significantly increased in the Ligated group compared to those of the Control, C75 and C150 groups. The serum IL-1β levels in the Ligated group were significantly higher than the Control group. The mean osteoblast numbers in the Ligated group were lower than those of the Control, C75 and C150 groups. The C150 groups showed significantly more osteoblasts than the Control group. The osteoclast numbers in the Ligated group increased significantly compared to the C75, C150 and control groups. Conclusion: This study demonstrates that systemic administration of curcumin at the 75 and 150mg/kg doses reduced alveolar bone loss in the periodontal disease in rats.Keywords: Alveolar bone loss, Antioxidant, Curcumin, Ligature-induced, Histomorphometric, Micronutrition

100 Deals associated with C-150

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	Preclinical	US	University of Kansas	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

C-150

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation